Bentsur Ron's Form 4 filing
Nuvectis Pharma, Inc. (NVCT) · filed May 18, 2023
- Accession no.
- 0001104659-23-062078
- Filed
- May 18, 2023
- Trade date
- May 16, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. Open-market purchases total $5.45K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bentsur RonCIK 0001251213 | Director, Officer (Chairman & CEO), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 16, 2023 | Common Stock | PPurchaseAcquired | +320 | $17.03F2 | +$5,449.6 | 3,228,649 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Includes 216,759 shares of restricted stock and 210,000 restricted stock units.
Referenced by the price of 1 transaction in Table I.